查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1638850

乳癌液體活體組織切片市場機會、成長促進因素、產業趨勢分析與預測 2024 - 2032

Breast Cancer Liquid Biopsy Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年，全球乳癌液體活體組織切片市場達到 3.059 億美元，預計 2024 年至 2032 年複合年成長率將達到 22.6%。包括新一代定序 (NGS) 在內的液體活體組織切片創新技術因其高精度和微創方法而受到關注，使早期檢測和個人化治療變得更加容易和有效。

人們對遺傳傾向和遺傳性癌症風險的認知不斷提高，進一步推動了對這些技術的需求。液體活體組織切片技術透過提供詳細的分子見解來幫助指導靶向癌症治療，從而支持更精確、個人化的治療計劃。

按生物標記類型細分，cfDNA 細分市場預計到2023 年將保持22.5% 的強勁複合年成長率。和疾病進展。與傳統的組織活體組織切片相比，cfDNA 提供了全面的基因組圖譜，並且可以檢測與抗藥性相關的新興突變，從而提高了其在癌症診斷中的實用性。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 3.059 億美元
預測值 19億美元
複合年成長率 22.6%

在產品和服務方面，市場分為試劑盒和試劑和服務產品，到2023年，試劑盒和試劑將佔據67.1%的佔有率。乳癌盛行率的上升增加了對這些試劑盒的需求，推動了早期癌症檢測領域的持續研究和新產品的推出。

2023年北美乳癌液體切片市場估值為1.333億美元。該國先進的醫療基礎設施和大量的研發投資促進了液體活體組織切片技術的實施，作為傳統方法的非侵入性替代品。美國乳癌發生率不斷上升，進一步刺激了對這些創新診斷工具的需求，凸顯了該地區在該市場的領導地位。

因此，在技術創新、早期癌症檢測工作以及對患者特異性治療策略的日益重視的推動下，全球乳癌液體活體組織切片市場預計將顯著成長。這種擴張反映了人們日益轉向微創診斷技術，以提高準確性並改善患者治療效果。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 乳癌盛行率上升
      • 液體切片技術的技術進步
      • 提高早期診斷和治療意識
      • 擴大研發
    • 產業陷阱與挑戰
      • 切片設備成本高
      • 嚴格的監管要求
  • 成長潛力分析
  • 流行病學情景
  • 監管環境
  • 技術景觀
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按生物標記，2021 - 2032 年

  • 主要趨勢
  • 循環腫瘤細胞 (CTC)
  • 遊離 DNA (cfDNA)
  • 外泌體
  • 其他生物標記

第 6 章：市場估計與預測：按產品和服務分類，2021 - 2032 年

  • 主要趨勢
  • 試劑盒和試劑
  • 服務

第 7 章：市場估計與預測：按樣本類型，2021 - 2032

  • 主要趨勢
  • 血
  • 尿
  • 其他樣品類型

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

  • 主要趨勢
  • 醫院
  • 癌症研究中心
  • 診斷中心
  • 學術及研究機構

第 9 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：公司簡介

  • Datar Cancer Genetics
  • Epic Sciences
  • F. Hoffmann-La Roche
  • Genes2me
  • Illumina
  • Menarini Silicon Biosystems
  • Myriad Genetics
  • OncoDNA
  • QIAGEN
  • Sysmex Corporation
  • System Biosciences
  • Thermo Fisher Scientific
  • Twist Bioscience
簡介目錄
Product Code: 12188

The Global Breast Cancer Liquid Biopsy Market reached USD 305.9 million in 2023 and is projected to expand at a robust CAGR of 22.6% from 2024 to 2032. Rising breast cancer incidence and advancements in diagnostic technologies are driving this growth. Liquid biopsy innovations, including next-generation sequencing (NGS), are gaining traction due to their high accuracy and minimally invasive methods, making early detection and personalized treatment more accessible and effective.

Increased awareness around genetic predispositions and inherited cancer risks is further fueling the demand for these technologies. Liquid biopsy techniques support more precise, individualized treatment plans by providing detailed molecular insights that help guide targeted cancer therapies.

Segmented by biomarker type, the market from cfDNA segment is expected to maintain a strong CAGR of 22.5% in 2023. This popularity is attributed to cfDNA's ability to reveal real-time tumor dynamics, offering early detection and insights into treatment response and disease progression. Compared to traditional tissue biopsies, cfDNA provides a comprehensive genomic profile and can detect emerging mutations linked to drug resistance, increasing its utility in cancer diagnostics.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$305.9 Million
Forecast Value$1.9 Billion
CAGR22.6%

In terms of products and services, the market is divided into kits & reagents and service offerings, with kits & reagents holding a significant 67.1% share in 2023. These components play a pivotal role in the liquid biopsy, thus facilitating non-invasive diagnostic procedures. The rising prevalence of breast cancer has intensified demand for these kits, driving ongoing research and new product launches in early cancer detection.

North America breast cancer liquid biopsy market in 2023, with a valuation of USD 133.3 million. The country's advanced healthcare infrastructure and substantial R&D investments foster the implementation of liquid biopsy technologies as non-invasive substitutes to traditional methods. The escalating incidence of breast cancer in the U.S. has further spurred demand for these innovative diagnostic tools, underscoring the region's leadership in this market.

As a result, the global breast cancer liquid biopsy market is expected to grow significantly, driven by technology innovations, early cancer detection efforts, and a growing emphasis on patient-specific treatment strategies. This expansion reflects the increasing shift toward minimally invasive diagnostic techniques that offer improved accuracy and patient outcomes.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of breast cancer
      • 3.2.1.2 Technological advancements in liquid biopsy technique
      • 3.2.1.3 Rising awareness for early diagnosis and treatment
      • 3.2.1.4 Expansion of research and development
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of biopsy devices
      • 3.2.2.2 Stringent regulatory requirements
  • 3.3 Growth potential analysis
  • 3.4 Epidemiology scenario
  • 3.5 Regulatory landscape
  • 3.6 Technological landscape
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Biomarkers, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Circulating Tumor Cells (CTCs)
  • 5.3 Cell-free DNA (cfDNA)
  • 5.4 Exosomes
  • 5.5 Other biomarkers

Chapter 6 Market Estimates and Forecast, By Product & Services, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Kits & reagents
  • 6.3 Services

Chapter 7 Market Estimates and Forecast, By Sample Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Blood
  • 7.3 Urine
  • 7.4 Other sample types

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Cancer research centers
  • 8.4 Diagnostic centers
  • 8.5 Academic and research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Datar Cancer Genetics
  • 10.2 Epic Sciences
  • 10.3 F. Hoffmann-La Roche
  • 10.4 Genes2me
  • 10.5 Illumina
  • 10.6 Menarini Silicon Biosystems
  • 10.7 Myriad Genetics
  • 10.8 OncoDNA
  • 10.9 QIAGEN
  • 10.10 Sysmex Corporation
  • 10.11 System Biosciences
  • 10.12 Thermo Fisher Scientific
  • 10.13 Twist Bioscience